Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors (Q37505849)

20 August 2017

1 reference

title

Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors (English)

1 reference

20 August 2017

Raymond O Estacio

1

1 reference

PubMed ID

19491538

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

Postgraduate Medicine

1 reference

20 August 2017

121

1 reference

20 August 2017

3

1 reference

20 August 2017

33-44

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

20 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Non-insulin-dependent diabetes mellitus in minorities in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Economic costs of diabetes in the U.S. In 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Epidemiology of Hypertension in Diabetic Patients and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

The course of incipient diabetic nephropathy: studies of albumin excretion and blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Changes of gene expression profiles in macrophages stimulated by angiotensin II--angiotensin II induces MCP-2 through AT1-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Frozen shoulder and other shoulder disturbances in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Kidney disease of diabetes mellitus (diabetic nephropathy): Perspectives in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Diabetic nephropathy: diagnosis, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

The paradox of the renin-angiotensin system in chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Renal protective effect of enalapril in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Heart failure: the frequent, forgotten, and often fatal complication of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Renin, prorenin and the putative (pro)renin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Novel drugs targeting hypertension: renin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Aspartic proteases in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Standards of medical care in diabetes--2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.05.2000

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.05.2000

1 reference

release_jgvjiwuugbchvafsf7z75ixa5e

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jgvjiwuugbchvafsf7z75ixa5e

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19491538

1 reference

PubMed ID

19491538